This is particularly timely given the current therapeutic landscape for PA and MAPK-driven low-grade glioma, in which MEK/RAF inhibitors are the subject of trials and are close to becoming first-line therapy [6, 7, 59]. The gene discussed is MAP2K7; the disease is central nervous system cancer.